The chairman of Medeva, Bernard Taylor, has indicated that management changes that were planned for some time ahead could now be brought forward as a result of its problems in the USA and the resulting profits warning which was announced last week (Marketletter July 26).
The changes are likely to include the splitting of Mr Taylor's role as chairman and chief executive. Mr Taylor told the Financial Times that he would like "several months to pass" before any changes are considered by the board.
Last week, Medeva's value on the UK stock market fell from L 589 million ($882.6 million) to L 295 million following the profits warning.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze